-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: iHuPDX in vivo drug efficacy model
Author:
InnoModels
Release time:
2024-04-02
In the field of biomedicine, the concepts of precision medicine and individualized therapy are gaining increasing attention. In order to achieve this goal, scientists are constantly looking for animal models that are closer to human diseases. The iHuPDX in vivo pharmacodynamic model of InnoModels Biotechnology was born in such a background, and provides a brand new perspective and tool for tumor drug research and development with its unique advantages.
1. Accurate simulation of human tumors
The iHuPDX model (i.e., "patient-derived xenograft model") uses patient tumor tissues directly transplanted into immunodeficient mice, which maintains the original structure, heterogeneity, and microenvironment of the tumor tissues to the greatest extent possible. This accurate simulation capability makes the iHuPDX model highly realistic in reflecting the biological characteristics of human tumors and drug responses.
2. Highly individualized
Each iHuPDX model is built based on the patient's tumor tissue, and therefore has highly individualized characteristics. This individualized model can not only be used to study the tumor characteristics of a specific patient, but also to tailor the treatment plan for each patient, realizing true precision medicine.
3. Powerful drug screening capability
The iHuPDX model provides an efficient in vivo screening platform for drug development. By observing the tumor response to drugs in mice, researchers can quickly screen potential drug candidates, greatly reducing the time and cost of drug development.

4. Predicting clinical trial results
An important advantage of the iHuPDX model is its ability to predict the efficacy of drugs in clinical trials. Through early evaluation of candidate drugs in the model, researchers can screen out the most likely successful drugs into clinical trials, thus improving the success rate of clinical trials.
5、Promote translational medical research
The iHuPDX model promotes the development of translational medicine as a bridge between basic research and clinical applications. Through the model, researchers can more deeply understand the biological characteristics of tumors and the mechanism of drug action, and provide more scientific and reliable therapeutic suggestions for the clinic.
6 VI. Ethics and Feasibility
Compared with traditional animal models, the iHuPDX model uses the patient's own tumor tissues, so it is more acceptable ethically. At the same time, the technology and process of the model establishment is quite mature, with high feasibility and reproducibility.
In summary, the iHuPDX in vivo drug efficacy model of InnoModels Biotechnology has opened up a new path for oncology drug discovery and development with its features of accurate simulation, high degree of individualization, powerful drug screening ability, prediction of clinical trial results, facilitation of translational medical research, as well as ethics and feasibility. With the continuous advancement of technology, the iHuPDX model is expected to play an increasingly important role in tumor research and clinical treatment.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd